Sanofi and Pieris expand research collaboration

Sanofi has announced an expansion of its collaborative relationship with biotechnology firm Pieris to include a new targeted protein therapeutics research programme.

The companies will ally on a novel programme to develop therapies based on multispecific Anticalin-branded proteins, which have been rationally engineered to solve the pharmacological and pharmaceutical limitations of both protein and non-protein-based drug platforms.

Because the DNA of individual Anticalins can be pieced together to create a fusion protein, it means they can offer new biology and synergistic efficacy by addressing multiple targets with a single drug.

Other benefits of this method include added convenience, faster development timelines, easier manufacturing and reduced costs.

Stephen Yoder, chief executive officer of Pieris, said: "Sanofi and Pieris will continue to advance both existing and new programmes, building on the excellent team chemistry between our organisations."

Last week, Sanofi announced a new collaboration with Schneider Electric that will allow the pharmaceutical company to improve the energy efficiency of its manufacturing network.